simvastatin has been researched along with Innate Inflammatory Response in 215 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.93) | 18.2507 |
| 2000's | 73 (33.95) | 29.6817 |
| 2010's | 105 (48.84) | 24.3611 |
| 2020's | 35 (16.28) | 2.80 |
| Authors | Studies |
|---|---|
| Edwards, BS; Graves, SW; Saunders, MJ; Sklar, LA; Zhu, J | 1 |
| DU, K; Lan, B; Leng, B; Liang, B; Yu, M; Zhang, Y; Zhao, N | 1 |
| Haczkiewicz-Leśniak, K; Kwiatkowska, J; Piasecki, T; Podhorska-Okołów, M; Sapa-Wojciechowska, A; Skrzypiec-Spring, M; Szeląg, A | 1 |
| Chen, J; Huang, MJ; Wu, XM; Xu, L; Zhang, YK | 1 |
| Fu, G; Huang, C; Huang, G; Li, J; Wei, T; Xu, J; Zhao, H; Zhu, X | 1 |
| Barreto, EA; Bou-Habib, DC; Bozza, FA; Bozza, PT; Cesar-Silva, D; Cunha-Fernandes, T; de Almeida, CJG; de Freitas, CS; Dias, SSG; Ferreira, AC; Fintelman-Rodrigues, N; Gonçalves, BS; Hottz, ED; Mattos, M; Palhinha, L; Pão, CRR; Pereira-Dutra, FS; Reis, PA; Sacramento, CQ; Saraiva, EM; Soares, VC; Souza, TML; Teixeira, L; Temerozo, JR; Viola, JPB | 1 |
| He, H; He, J; Liu, J; Liu, X; Ma, S; Xu, F; Zhang, M; Zhang, W; Zhou, X | 1 |
| Chen, S; Chen, T; Fu, X; Huo, R; Li, L; Liang, Z; Lin, J; Lin, W; Pan, B; Wang, X; Xu, C | 1 |
| Cowen, PJ; De Giorgi, R; Harmer, CJ; Quinton, AMG; Waters, S | 1 |
| Gu, Y; Lu, Y; Tan, Y; Wang, X; Yao, Z; Yu, X; Zha, S | 1 |
| Beede, K; Christiansen, DL; Hattervig, RL; Killeen, AC; Nawshad, A; Ramer-Tait, A; Reinhardt, RA; Samson, KK | 1 |
| Alabed, M; Elemam, NM; Hafezi, S; Halwani, R; Kalaji, Z; Mdkhana, B; Saheb Sharif-Askari, F; Saheb Sharif-Askari, N; Salam Bayram, O; Selvakumar, B | 1 |
| Chen, YR; Liu, D; Peng, B; Sun, F; Xiang, XD; Xiao, BW; Yan, MY | 1 |
| Jougasaki, M; Sudou, K; Takenoshita, Y; Tokito, A; Umebashi, K; Yamamoto, M | 1 |
| Atyabi, F; Dinarvand, R; Kharazian, B; Khonsari, F; Kiani, M; Moraffah, F; Shokrgozar, MA | 1 |
| Abolmaali, SS; Azarpira, N; Heidari, R; Janipour, Z; Najafi, H; Özyılmaz, ED; Tamaddon, AM | 1 |
| Landh, E; Ong, HX; Pisano, E; Scalia, S; Traini, D; Tulbah, AS; Young, PM | 1 |
| Manickavasagam, D; Oyewumi, MO | 1 |
| Hamel, E; Royea, J; Tong, XK; Trigiani, LJ | 1 |
| Lin, L; Manickavasagam, D; Oyewumi, MO | 1 |
| Agrawal, A; Ahmad, M; Ahmad, T; Ghosh, B; Khanna, K; Kulshreshtha, A; Singh, S | 1 |
| Li, SJ; Li, YP; Ma, LN; Shen, ML; Wu, XD; Yao, SY; Zhang, MM | 1 |
| Fares, N; Hajal, J; Irani, C; Layoun, H; Maalouly, G; Rached, G; Saliba, Y; Sleilaty, G; Smayra, V | 1 |
| Fan, H; Huang, J; Lai, X; Liu, A; Qiao, L; Shen, M; Wu, J; Yan, J | 1 |
| Chen, J; Chen, L; Chen, Y; Liu, J; Lu, Y; Pan, W; Yan, C; Zhang, C; Zhang, W | 1 |
| Huang, L; Huang, Y; Nie, W; Wei, W; Wu, G; Xi, X; Xie, HY; Yuan, L; Zhang, J; Zuo, L | 1 |
| Alberici, LC; Cárnio, EC; Catalão, CHR; da Costa, LHA; Rocha, MJA; Santos-Junior, NN; Sebollela, A; Souza, AO | 1 |
| Grochot-Przęczek, A; Hajduk, K; Józkowicz, A; Klóska, D; Kopacz, A; Neumayer, C; Piechota-Polanczyk, A; Werner, E | 1 |
| Amidžić, L; Gajanin, R; Jaćević, V; Kuča, K; Milovanović, Z; Nepovimova, E; Nežić, L; Škrbić, R | 1 |
| Li, Q; Liu, SH; Song, FC; Yuan, JQ; Zhang, L; Zhao, C; Zhao, K; Zhu, MD | 1 |
| Bozza, PT; de Castro Faria Neto, HC; de Jesus Oliveira, FM; de Moraes, IMM; Gonçalves-de-Albuquerque, CF; Reis, PA; Rocha, VN; Silva, AR | 1 |
| Bai, L; Li, R; Li, S; Liu, Q; Liu, Y; Wang, Y; Wen, Y | 1 |
| Cai, C; Kilari, S; Korley, JN; Misra, S; Simeon, M; Singh, A; von Recum, HA; Zhao, C; Zuckerman, ST | 1 |
| Liao, SL; Tang, WC; Wang, CC; Wang, SH; Wei, YH; Yang, CH | 1 |
| Kim, DH; Kim, H; Lee, CW; Lee, JS; Lee, PH; Lee, SW; Moon, DH; Oh, M; Shin, EW; Sung, C | 1 |
| Abdel-Rafei, MK; Moustafa, EM; Rashed, ER; Thabet, NM | 1 |
| Cao, Y; Darwitan, A; Das, P; Muktabar, A; Ng, KW; Nguyen, LTH; Rakshit, M; Tang, J; Venkatraman, S; Vizetto-Duarte, C; Wong, YS | 1 |
| Basinska, T; Czuczwar, S; Dabrowski, W; Gadzinowski, M; Kocki, J; Oru, N; Slomkowski, S; Szumilo, J; Vicaut, E; Wacinski, J; Wacinski, P | 1 |
| Florean, EOPT; Guedes, MIF; Holanda, MO; Lima, CLS; Lira, SM; Marques, MMM; Mendes, FNP; Moura, LFWG; Oriá, RB; Paim, RTT; Rodrigues, PAS; Silva, BBD; Silva, JYGD; Vieira, IGP | 1 |
| Feng, Y; Lei, B; Niu, L; Zhang, F; Zhang, H; Zhang, M | 1 |
| Guo, J; Liu, Q; Lu, M; Luo, D; Rong, X; Tang, F; Wang, H; Yang, Y; Yin, M; Yu, L | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| Bernik, MMS; Cerda, A; Dorea, EL; Fajardo, CM; Guimarães, ES; Gusukuma, MC; Hirata, MH; Hirata, RDC; Pinto, GA | 1 |
| Ong, HX; Pisano, E; Scalia, S; Traini, D; Tulbah, AS; Young, PM | 1 |
| Kolodziejczyk, AM; Szymonski, M; Targosz-Korecka, M | 1 |
| Al-Ajmi, HN; Al-Amin, MA; Al-Rasheed, NM; Hasan, IH; Mahmoud, AM; Mohamad, RA | 1 |
| Campos-Martorell, M; Hernandez-Guillamón, M; Montaner, J; Simats, A; Solé, M; Sun, P; Unzeta, M | 1 |
| de Souza Costa, CA; Eyster, TW; Ma, PX; Mohamed, F; Soares, DG; Zhang, Z | 1 |
| Ekinci, A; Erdoğan, AS; Kesici, H; Koc, S | 1 |
| Ahangari, Z; Dianat, O; Mashhadiabbas, F; Motamedian, SR; Saedi, S | 1 |
| Vogt, L; Waters, DD | 1 |
| Cai, M; Kalavagunta, PK; Liu, Q; Lv, W; Pan, Q; Qin, G; Shang, J; Wang, T; Wu, H; Xia, Z; Zhou, L | 1 |
| Boyle, AK; Norman, JE; Rinaldi, SF; Rossi, AG; Saunders, PTK | 1 |
| Chrøis, KM; Dela, F; Dohlmann, TL; Hansen, M; Helge, JW; Kelly, B; Kuhlman, ACB; Larsen, S; Morville, T; Sahl, RE | 1 |
| Barale, C; Cavalot, F; Frascaroli, C; Russo, I; Senkeev, R | 1 |
| Belmonte-de-Abreu, PS; Ceresér, KM; Cordova, VHS; Dias da Rosa, E; Francesconi, LP; Jacobus, RVM; Oliveira, L; Salah, IA; Victorino, AT | 1 |
| An, YQ; Dai, Y; Hu, LF; Lin, GY; Tang, CR; Xu, HQ; Xu, RA; Yu, XB; Zhang, CH; Zhang, HN; Zhou, ZY | 1 |
| Al Humayed, S; Alassiri, M; Aldera, H; Alkhateeb, MA; Shati, AA; Shatoor, AS; Shatoor, KA | 1 |
| Han, Q; Liu, Q; Lu, M; Tang, F; Wang, H; Zhang, H; Zhang, Y | 1 |
| Chen, HJ; Cho, CL; Liang, CL; Liliang, PC; Lu, K; Tsai, YD; Wang, HK; Wang, KW | 2 |
| Abdalla, FH; Bernardes, VM; Braun, JBS; Casali, EA; Castilhos, LG; da Cruz, IBM; de Andrade, CM; de Oliveira, JS; Leal, DBR; Manzoni, AG; Passos, DF; Ruchel, JB | 1 |
| Bona, S; Di Naso, FC; Dias, AS; Marroni, CA; Marroni, NP; Moreira, AJ; Picada, JN; Pires, TR; Rodrigues, G; Schemitt, E | 1 |
| Dhaygude, K; Helanterä, I; Holmström, EJ; Jokinen, JJ; Kankainen, M; Krebs, R; Lemström, KB; Lommi, J; Nykänen, AI; Räisänen-Sokolowski, A; Syrjälä, SO; Tuuminen, R | 1 |
| Bebawy, M; Buttini, F; Colombo, P; Haghi, M; Marin, L; Ong, HX; Traini, D; Young, P | 1 |
| Chen, RZ; Ge, JB; Jia, JG; Jiang, H; Liu, M; Yu, P; Yu, Y; Zhang, L; Zhang, PP; Zou, YZ | 1 |
| Gitirana, LB; Machado, MN; Magalhães, CB; Melo, AC; Porto, LC; Ribeiro, ML; Santos, JC; Valença, SS; Zin, WA | 1 |
| Backman, JT; Calfee, CS; Duffy, MJ; Elborn, SJ; Griffiths, MJ; Johnston, JR; MacSweeney, R; Matthay, MM; McAuley, DF; McDowell, C; McGuigan, J; OʼKane, CM; Shields, MO; Shyamsundar, M | 1 |
| Dong, L; Qu, X; Shen, F; Zhang, X; Zhao, X | 1 |
| Badimon, L; de la Torre, R; Peña, E; Slevin, M; Vilahur, G | 1 |
| Han, JJ; Li, QZ; Qian, ZJ; Sun, J | 1 |
| Costa, TP; Fávero, GM; Fernandes, D; Machado, WM; Mendes, RT; Olchanheski, LR; Otuki, MF; Prestes, AP; Santos, FA; Sordi, R; Vellosa, JC | 1 |
| Barbosa, CP; Bersani-Amado, CA; Cuman, RK; da Silva, LG; Grespan, R; Hernandes, L; Ritter, AM | 1 |
| Alcala, SE; Anderson, J; Benton, AS; Damsker, J; Freishtat, RJ; Hayes, K; Hoffman, EP; Kureshi, S; Lee, AJ; Nagaraju, K; Reeves, EM; Rose, MC; Wang, Z; Watson, AM; Williams, AM | 1 |
| Almquist, T; Hjemdahl, P; Jacobson, SH; Mobarrez, F; Näsman, P | 1 |
| Anticoli, S; Gambardella, L; Malorni, W; Maselli, A; Matarrese, P; Panusa, A; Ruggieri, A; Vona, R | 1 |
| Chen, HJ; Cho, CL; Liang, CL; Liliang, PC; Lu, K; Tsai, YD; Wang, KW | 1 |
| Chen, B; Ding, W; Feng, Q; Huang, Z; Jiang, L; Li, W; Luo, Q; Luo, W; Pan, H; Wei, W; Wu, B; Xu, G; Zhao, Y | 1 |
| Allon, DM; Allon, I; Anavi, Y | 1 |
| Lee, SI; Liu, JN; Park, HS; Shin, YS; Suh, DH; Yang, EM | 1 |
| Bedi, A; Davis, ME; Gumucio, JP; Harning, JA; Korn, MA; Mendias, CL; Saripalli, AL | 1 |
| Chen, J; Guan, N; Huo, X; Sun, D; Xi, H; Zhang, F | 1 |
| Huang, CJ; Kao, MC; Li, KY; Shih, PC; Tsai, PS; Yang, CH | 1 |
| Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A | 1 |
| Jiang, X; Li, Z; Sun, W; Wang, L; Wang, Y; Zhang, L | 1 |
| Andrade, VL; Béla, SR; de Assis Martins-Filho, O; de Moraes, TF; Fernandes, KS; Sandrim, VC | 1 |
| Basraon, SK; Costantine, MM; Menon, R; Saade, G | 1 |
| Bourre, B; Lefaucheur, R; Maltête, D; Ozkul-Wermester, O; Wallon, D | 1 |
| D'Hooge, R; Gieselmann, V; Matzner, U; Stein, A; Stroobants, S | 1 |
| Hu, Y; Liu, K; Miao, C; Ren, L; Sun, B; Yan, M; Zhang, Y | 1 |
| Câmara, NO; Cenedeze, MA; de Oliveira, DM; de Oliveira, EM; Ferrari, Mde F; Hiyane, MI; Pacheco-Silva, A; Peron, JP; Semedo, P | 1 |
| Chen, W; Cress, AE; Dull, RO; Epshtein, Y; Garcia, JG; Jacobson, JR; Ni, X | 1 |
| Aragonez, A; Bobinski, F; Cordeiro, MM; Corrêa, M; de Freitas, SF; dos Santos, AR; Encarnação, IC; Goldfeder, EM; Xavier, CC | 1 |
| Deng, X; Li, C; Ren, W; Wang, S; Xiong, L; Zhou, Q; Zhu, C | 2 |
| Engqvist, H; Karlsson Ott, M; Mestres, G; Montazerolghaem, M; Ning, Y; Tenje, M | 1 |
| Alaarg, A; da Silva, AE; Hamers, AA; Metselaar, JM; Schulte, DM; Storm, G; Stroes, ES; van der Valk, FM; van Ufford, LC; Versloot, M; Zheng, KH | 1 |
| Colombo, P; Ong, HX; Traini, D; Tulbah, AS; Young, PM | 1 |
| Israsena, N; Patumraj, S; Sukpat, S | 1 |
| Chang, CH; Chio, CC; Hu, CY; Kuo, JR; Liao, JC; Lim, SW; Shiue, YL; Wang, CC; Wee, HY | 1 |
| Ghadiali, SN; Higuita-Castro, N; Mihai, C; Shukla, VC | 1 |
| Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A | 1 |
| Cui, R; Ding, T; Gu, W; Guo, X; Han, F; Li, X; Peng, J; Xu, W | 1 |
| Dong, X; Shi, D | 1 |
| Li, Y; Liu, J; Pang, X; Si, J; Xu, S | 1 |
| Ames, FQ; Barbosa, CP; Bersani-Amado, CA; Bracht, L; de Souza Silva-Comar, FM; Tronco, RP | 1 |
| Amani, A; Deiham, B; Doosti, M; Faramarzi, MA; Imanparast, F; Kobarfard, F; Paknejad, M; Vatannejad, A | 1 |
| Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH | 1 |
| Chade, AR; Daghini, E; Lavi, R; Lerman, A; Lerman, LO; Napoli, C; Zhu, XY | 1 |
| Im, DS; Kimura, T; Kurose, H; Kuwabara, A; Mogi, C; Murakami, M; Okajima, F; Sato, K; Tomura, H | 1 |
| Dobrić, S; Jaćević, V; Milovanović, ZA; Nezić, L; Satara, SS; Skrbić, R; Stojaković, N; Stojiljković, MP | 1 |
| Ji, G; Liang, X; Liu, J; Liu, T; Ma, Z; Wu, H; Xin, L; Zheng, P | 1 |
| Aragoncillo, P; Fernández-Cruz, A; Gómez-Garre, D; González-Rubio, ML; Granados, R; Muñoz-Pacheco, P | 1 |
| Aoyama, I; Bomsztyk, K; Komers, R; Koopmeiners, JS; Naito, M; Schnaper, HW; Shenoy, A | 1 |
| Ozeç, I | 1 |
| Andrade, JM; Araújo, AL; Carvalho, LS; Cintra, RM; Coelho, OR; Ono, AH; Quinaglia e Silva, JC; Sposito, AC | 1 |
| Akinci, B; Bayraktar, F; Comlekci, A; Demir, T; Ozcan, MA; Yener, S; Yesil, S; Yuksel, F | 1 |
| Franzi, L; Kenyon, NJ; Last, J; Zeki, AA | 1 |
| Kitas, GD; Melas, N; Saratzis, A; Saratzis, N | 1 |
| Tomkin, GH | 1 |
| Blazing, MA; Califf, RM; de Lemos, JA; Fox, K; Lewis, EF; Mielniczuk, LM; Mohanavelu, S; Pedersen, TR; Pfeffer, MA; Rouleau, J | 1 |
| Baldari, CT; Benati, D; Ferro, M; Nuccitelli, A; Pasini, FL; Savino, MT; Schiavo, E; Ulivieri, C | 1 |
| Dobrić, S; Milovanović, ZA; Nezić, L; Satara, SS; Skrbić, R; Stojaković, N; Stojiljković, MP | 1 |
| Armbruster, FP; Efstrathios, K; Forst, T; Hanefeld, M; Löbig, M; Pfützner, A | 1 |
| Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA | 1 |
| Cengiz, SD; Dünder, I; Kaya, C; Pabuccu, R | 1 |
| Chade, AR; Lavi, R; Lerman, A; Lerman, LO; Lin, J; Zhu, XY | 1 |
| Barber, MJ; Chasman, DI; Chatterjee, A; Hyde, CL; Krauss, RM; Li, X; Mangravite, LM; McCarty, CA; Nickerson, DA; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Wilke, RA; Williams, PT | 1 |
| Chambers, JB; Viljoen, A; Wierzbicki, AS | 1 |
| Dorlechter, F; Farah, R; Shurtz-Swirski, R | 1 |
| Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS | 1 |
| Craig, TR; Duffy, MJ; Elborn, JS; McAuley, DF; McDowell, C; O'Kane, CM; Shyamsundar, M | 1 |
| Alexopoulos, E; Belechri, AM; Dogrammatzi, F; Efstratiadis, G; Kirmizis, D; Memmos, D; Papagianni, A; Skoura, L | 1 |
| Gdula-Dymek, A; Krysiak, R; Okopień, B; Scieszka, J | 1 |
| Bratt, JM; Kenyon, NJ; Last, JA; Rabowsky, M; Zeki, AA | 1 |
| Anyfantakis, ZA; Cokkinos, DV; Degiannis, D; Iakovis, P; Kroupis, C; Limas, C | 1 |
| Bereswill, S; Fischer, A; Göbel, UB; Haag, LM; Heimesaat, MM; Kühl, AA; Loddenkemper, C; Muñoz, M; Otto, B; Plickert, R | 1 |
| Cheriyan, J; Cherry, L; Davidson, EH; Kharbanda, RK; Mäki-Petäjä, KM; McEniery, CM; Sattar, N; Wallace, SM; Wilkinson, IB | 1 |
| Krysiak, R; Okopien, B | 2 |
| Capuano, A; Cuzzocrea, S; Di Palma, D; Donniacuo, M; Esposito, E; Mazzon, E; Paterniti, I; Rinaldi, B; Rossi, F; Sodano, L | 1 |
| Abediasl, J; Rahmanpour, H; Rashidi, B; Sills, ES; Tehraninejad, E | 1 |
| Krysiak, R; Okopien, B; Zmuda, W | 1 |
| Bai, N; Eom, J; Jaw, JE; Li, Y; Man, SP; Mui, T; Ngan, D; Or, C; Sin, DD; Suda, K; Tam, S; Tsuruta, M; Van Eeden, S; Wang, X | 1 |
| Chou, TC; Chou, WH; Leung, PO; Lu, SH; Shiau, CY; Wang, SH | 1 |
| Bakris, G; de Guzman, E; Lazich, I; Oliva, R; Patel, A; Sarafidis, P | 1 |
| Chen, KJ; Guo, CY; Huang, Y; Ma, XJ; Shi, DZ; Wu, CF; Xue, M; Yin, HJ | 1 |
| Bierhaus, A; Djuric, Z; Fleming, T; Grafe, IA; Groener, JB; Metzner, C; Nawroth, PP; Reismann, P; Rudofsky, G | 1 |
| Chen, W; Garcia, JG; Jacobson, JR; Ma, SF; Mitra, S; Sammani, S | 1 |
| Li, LJ; Li, M; Peng, L; Xu, YZ; Yang, C; Zhang, GY; Zhang, JP; Zhou, YN | 1 |
| Chung, MH; Lee, CS; Lee, JK; Lee, JW; Lee, YJ; Shin, MK; Sung, SH; Won, C; Yang, YM; Ye, SK; Yi, EH | 1 |
| Basraon, SK; Costantine, MM; Hankins, GD; Longo, M; Makhlouf, M; Menon, R; Saade, GR | 1 |
| Alexopoulos, E; Belechri, AM; Dogrammatzi, F; Efstratiadis, G; Kirmizis, D; Memmos, D; Papagianni, A | 1 |
| Jeppsson, B; Lepsenyi, M; Luo, L; Rahman, M; Syk, I; Thorlacius, H; Wang, Y; Zhang, S | 1 |
| Bratt, JM; Davis, BB; Filosto, S; Goldkorn, T; Kenyon, NJ; Pinkerton, KE; Schelegle, ES; Walby, WF; Wang, L; Zeki, AA | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Ahn, JY; Choi, IS; Choi, YM; Jeong, EM; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Park, GS; Shin, EK; Son, JW | 1 |
| Lefer, DJ | 1 |
| Alber, HF; Ares, MP; Dichtl, W; Dulak, J; Frick, M; Nilsson, J; Pachinger, O; Schwarzacher, SP; Weidinger, F | 1 |
| Artese, L; Bajocchi, G; Bei, R; Chiarelli, F; Cipollone, F; Cuccurullo, F; De Cesare, D; Fazia, M; Iezzi, A; Mezzetti, A; Muraro, R; Piattelli, A; Pini, B; Spigonardo, F; Ucchino, S; Zucchelli, M | 1 |
| Ansell, BJ; Dave, R; Fogelman, AM; Fonarow, G; Hama, S; Hough, G; Kamranpour, N; Mottahedeh, R; Navab, M; Rahmani, S; Reddy, ST | 1 |
| Antunes-Rodrigues, J; Carnio, EC; da Rocha, MJ; Elias, LL; Felix, JV; Giusti-Paiva, A; Martinez, MR | 1 |
| Fang, CH; Li, JJ | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Li, Q; Liu, L; Xiao, J; Xu, Z; Zhao, S | 1 |
| Aderem, A; Einhaus, D; Gold, ES; Matsumoto, M | 1 |
| Ahn, JY; Ahn, TH; Choi, YM; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Shin, EK; Son, JW | 1 |
| Hryszko, T; Malyszko, J; Malyszko, JS; Mysliwiec, M | 1 |
| Lavoie, J; Nattel, S; Schram, G; Shiroshita-Takeshita, A | 1 |
| Kapiotis, S; Marsik, C; Mittermayer, F; Pleiner, J; Polterauer, S; Schaller, G; Wolzt, M; Zorn, S | 1 |
| Barnard, JW; Garcia, JG; Grigoryev, DN; Jacobson, JR; Ma, SF; Tuder, RM | 1 |
| Huber, K; Kaun, C; Kopp, CW; Minar, E; Pleiner, J; Seidinger, D; Speidl, WS; Steiner, S; Wojta, J; Wolzt, M; Zorn, G | 1 |
| Campana, V; Gavotto, A; Moya, M; Palma, J; Simes, J; Spitale, L | 1 |
| Choe, KH; Kim, EK; Kim, SE; Lee, DS; Lee, JH; Lee, SD; Lee, YS; Oh, YM; Shim, TS | 1 |
| Alexander, MJ; Blessing, R; Coon, AL; Floyd, J; Friedman, AH; Graffagnino, C; Laskowitz, DT; Lynch, JR; McGirt, MJ; Wang, H; Warner, DS | 1 |
| Agrawal, A; Voleti, B | 1 |
| Celinska-Löwenhoff, M; Domagala, TB; Dropinski, J; Iwaniec, T; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Ferns, GA; Ghayour-Mobarhan, M; Lamb, DJ; Livingstone, C; Taylor, A; Vaidya, N; Wang, T | 1 |
| Erikstrup, C; Pedersen, BK; Ullum, H | 1 |
| Celinska-Lowenhoff, M; Potaczek, DP; Szczeklik, A; Undas, A | 1 |
| Bitter-Suermann, S; Kanniess, F; Magnussen, H; Watz, H | 1 |
| Chow, SC; Coward, WR; Marei, A; Vasa-Nicotera, MM; Yang, A | 1 |
| Dörge, H; Grabedünkel, J; Liakopoulos, OJ; Nagorsnik, U; Schmitto, JD; Schoendube, FA | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD | 1 |
| Gratsianskiĭ, NA; Masenko, VP; Smetanina, IN; Vaulin, NA | 1 |
| Chan, E; Devaraj, S; Jialal, I | 1 |
| Frenkel, J; Kuijk, LM; Mandey, SH; Waterham, HR | 1 |
| Baba, K; Hayabuchi, N; Imaizumi, T; Ishibashi, M; Kai, H; Kaida, H; Nakaura, H; Tahara, N | 1 |
| Gans, RO; May, JF; Mulder, DJ; Smit, AJ; Tervaert, JW; van Doormaal, JJ; van Haelst, PL; Wobbes, MH; Zijlstra, F | 1 |
| Abbate, M; Banfi, C; Bellosta, S; Brioschi, M; Canavesi, M; Gelosa, P; Gianella, A; Guerrini, U; Mussoni, L; Nobili, E; Remuzzi, G; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C | 1 |
| Devaraj, S; Griffen, SC; Jialal, I; Miguelino, E | 1 |
| Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A | 1 |
| Desai, JB; Driver, C; El Gamel, A; Grieve, D; John, LC; Kearney, MT; Marrinan, MT; Melikian, N; Momin, A; Shah, AM; Sherwood, R; Wheatcroft, SB | 1 |
| Booth, AD; Brown, J; Hall, FC; Mäki-Petäjä, KM; McEniery, CM; Wallace, SM; Wilkinson, IB | 1 |
| Kasugai, S; Kobayashi, H; Machida, T; Nakamura, T; Nyan, M; Oda, M; Sato, D | 1 |
| Azzellino, A; Balestri, G; Cazzaniga, M; Cerrito, MG; Cusa, EN; DeCarlini, C; Ferrari, AU; Garducci, S; Guerra, L; Lavitrano, ML; Loardi, C; Mancia, G; Menicanti, L; Paolini, G; Radaelli, A; Santo, D | 1 |
| Kanda, H; Kohno, C; Komagata, Y; Mimura, T; Sato, K; Sawada, T; Shimada, K; Yamaguchi, M; Yamamoto, K; Yokota, K | 1 |
| Li, F; Wang, CH; Zhang, W; Zhu, WZ | 1 |
| Dong, G; Jing, H; Liu, H; Qiang, J; Shao, H; Shen, Y | 1 |
| Fromes, Y | 1 |
| Argüelles, S; Cano, J; de Pablos, RM; Delgado-Cortés, MJ; Hernández-Romero, MC; Herrera, AJ; Machado, A; Santiago, M; Villarán, RF | 1 |
| Lai, LP; Liang, YJ; Shyu, KG; Wang, BW | 1 |
| Eisendle, K; Fritsch, P; Linder, D; Philipp, W; Piza, H; Ratzinger, G; Schmuth, M; Zelger, B | 1 |
| Jilma, B; Müller, M; Schmidt, WM; Spiel, AO; Wolzt, M | 1 |
| András, IE; Couraud, PO; Eum, S; Hennig, B; Huang, W; Rha, G; Romero, IA; Toborek, M | 1 |
| Stein, EA | 1 |
| Firbas, C; Jilma, B; Leitner, JM; Mayr, FB; Sieghart, W; Spiel, AO | 1 |
| Devaraj, S; Jialal, I; Rockwood, J; Wang, L; Zak, D | 1 |
| Bateman, TM; Conn, RD; Lavie, CJ; O'Keefe, JH | 1 |
| Rosenson, RS; Tangney, CC | 1 |
| Gajewski, P; Jankowski, M; Musial, J; Sydor, W; Szczeklik, A; Undas, A | 1 |
| Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M | 1 |
| Garrett, IR; Gutierrez, G; Mundy, GR | 1 |
| Hurt-Camejo, E; Mattsson-Hultén, L; Oscarsson, J; Wiklund, O | 1 |
7 review(s) available for simvastatin and Innate Inflammatory Response
| Article | Year |
|---|---|
Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung; Lung Diseases; Simvastatin | 2016 |
Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Blood Vessels; Cardiovascular Agents; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinases; Models, Animal; Pyrroles; Risk Assessment; Simvastatin | 2010 |
Aortic stenosis and lipids: does intervention work?
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Biomarkers, Pharmacological; Calcinosis; Disease Progression; Endothelium, Vascular; Ezetimibe; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Simvastatin; Stress, Physiological | 2010 |
[Pharmacological treatment of COPD and future of anti-inflammatory therapy].
Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Bronchodilator Agents; Carboxylic Acids; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Dyspnea; Expectorants; Forced Expiratory Volume; Forecasting; Humans; Inflammation; Infliximab; Lung; Macrolides; Nitriles; Phosphodiesterase Inhibitors; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research; Respiratory Function Tests; Simvastatin; Smoking Cessation; Tetracycline; Theophylline; Tumor Necrosis Factor-alpha | 2006 |
The new paradigm for coronary artery disease: altering risk factors, atherosclerotic plaques, and clinical prognosis.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antioxidants; Coronary Angiography; Coronary Artery Disease; Endothelium, Vascular; Exercise Test; Humans; Hypercholesterolemia; Inflammation; Lovastatin; Platelet Aggregation Inhibitors; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 1996 |
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Topics: Animals; Antithrombins; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Endothelium, Vascular; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lovastatin; Muscle, Smooth, Vascular; Platelet Aggregation; Pravastatin; Simvastatin; Thromboplastin; Thrombosis | 1998 |
Statins and bone formation.
Topics: Animals; Bone Development; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lovastatin; Neoplasms; Nitric Oxide Synthase; Pyridines; Simvastatin | 2001 |
47 trial(s) available for simvastatin and Innate Inflammatory Response
| Article | Year |
|---|---|
An experimental medicine study of the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation in healthy volunteers.
Topics: Biomedical Research; Double-Blind Method; Female; Healthy Volunteers; Humans; Inflammation; Reward; Simvastatin; Verbal Learning | 2022 |
Local simvastatin and inflammation during periodontal mini-flap wound healing: Exploratory results.
Topics: Dental Scaling; Follow-Up Studies; Gingival Crevicular Fluid; Humans; Inflammation; Interleukin-10; Interleukin-6; Simvastatin; Vascular Endothelial Growth Factor A; Wound Healing | 2023 |
Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation.
Topics: Adult; Aged; Atherosclerosis; Biomarkers; C-Reactive Protein; Cytokines; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Inflammation; Male; Middle Aged; Simvastatin; Ubiquinone | 2019 |
Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia.
Topics: Adult; Aged; Biomarkers; Cytokines; E-Selectin; Female; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; P-Selectin; Platelet Activation; Simvastatin | 2018 |
Donor Simvastatin Treatment in Heart Transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Chemokine CXCL10; Double-Blind Method; Female; Graft Rejection; Heart Transplantation; Hemodynamics; Humans; Inflammation; Male; Middle Aged; Reperfusion Injury; Simvastatin; Tissue Donors; Transplantation, Homologous; Troponin T; Young Adult | 2019 |
Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy: a randomized placebo-controlled trial.
Topics: Acute Lung Injury; Aged; Double-Blind Method; Endothelium; Esophageal Neoplasms; Esophagectomy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pulmonary Alveoli; Simvastatin | 2014 |
Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Case-Control Studies; Chemokine CCL2; Cross-Over Studies; Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Inflammation; Inflammation Mediators; Interferon-gamma; Male; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2014 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Healthy Volunteers; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; NF-kappa B; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Taurine; Triglycerides; Tryptophan; Uric Acid | 2015 |
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Pressure; Carboxypeptidase B2; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Simvastatin; Thiazolidinediones | 2009 |
Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Inflammation; Insulin; Insulin Resistance; Luteinizing Hormone; Oxidative Stress; Polycystic Ovary Syndrome; Prospective Studies; Pyrroles; Simvastatin; Testosterone; Young Adult | 2010 |
Genome-wide association of lipid-lowering response to statins in combined study populations.
Topics: Adult; Aged; Atorvastatin; Bayes Theorem; Cholesterol; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2010 |
A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study).
Topics: Acute Lung Injury; Bronchoalveolar Lavage Fluid; C-Reactive Protein; Cytokines; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multiple Organ Failure; Simvastatin; Treatment Outcome | 2011 |
Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy.
Topics: Cardiomyopathy, Dilated; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Prospective Studies; Simvastatin | 2011 |
Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction.
Topics: Adult; Aorta; Aortic Diseases; Blood Flow Velocity; Double-Blind Method; Endothelium, Vascular; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Lipids; Male; Salmonella typhi; Salmonella Vaccines; Simvastatin; Vasodilation; Young Adult | 2010 |
Simvastatin effects on androgens, inflammatory mediators, and endogenous pituitary gonadotropins among patients with PCOS undergoing IVF: results from a prospective, randomized, placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Androgens; Anticholesteremic Agents; Double-Blind Method; Female; Fertilization in Vitro; Gonadotropins; Gonadotropins, Pituitary; Humans; Inflammation; Ovulation Induction; Pituitary Gland; Polycystic Ovary Syndrome; Prospective Studies; Simvastatin; Testosterone | 2011 |
The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels.
Topics: Anticholesteremic Agents; Azetidines; Cytokines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Inflammation; Lymphocytes; Male; Middle Aged; Prospective Studies; Simvastatin | 2012 |
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Isoprostanes; Lipids; Male; Malondialdehyde; Metabolic Syndrome; Middle Aged; Oxidative Stress; Rosiglitazone; Simvastatin; Thiazolidinediones | 2012 |
Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe.
Topics: Aged; Anti-Inflammatory Agents; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Combinations; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Ezetimibe, Simvastatin Drug Combination; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Inflammation Mediators; Interleukin-6; Male; Middle Aged; NF-kappa B; Simvastatin; Time Factors; Treatment Outcome | 2012 |
The effects of vitamin E-coated membrane dialyzer compared to simvastatin in patients on chronic hemodialysis.
Topics: Acrylamides; Aged; Antioxidants; beta-Alanine; Biomarkers; C-Reactive Protein; Coated Materials, Biocompatible; Cross-Over Studies; Equipment Design; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Failure, Chronic; Male; Membranes, Artificial; Middle Aged; Oxidative Stress; Renal Dialysis; Simvastatin; Treatment Outcome; Vitamin E | 2012 |
Monocyte-suppressing effects of simvastatin in patients with isolated hypertriglyceridemia.
Topics: Adult; Biological Availability; Blood Glucose; C-Reactive Protein; Cell Physiological Phenomena; Cytokines; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Lipids; Male; Middle Aged; Monocytes; Peripheral Arterial Disease; Simvastatin; Treatment Outcome | 2013 |
Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease.
Topics: Biomarkers; C-Reactive Protein; Coronary Artery Disease; Diet; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Matrix Metalloproteinases; Middle Aged; Nitric Oxide; Prospective Studies; Simvastatin; Single-Blind Method; Tumor Necrosis Factor-alpha; Vasomotor System | 2002 |
Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.
Topics: Aged; Carotid Stenosis; Cell Movement; Cells, Cultured; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Enzyme Inhibitors; Extracellular Matrix; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Intramolecular Oxidoreductases; Isoenzymes; Macrophage Activation; Macrophages; Male; Matrix Metalloproteinases; Membrane Proteins; Prostaglandin-E Synthases; Prostaglandin-Endoperoxide Synthases; Simvastatin; T-Lymphocytes | 2003 |
Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Chemotaxis; Cholesterol, HDL; Cholesterol, LDL; Coculture Techniques; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lipids; Lipoproteins, HDL; Male; Middle Aged; Monocytes; Predictive Value of Tests; Simvastatin; Treatment Outcome; Triglycerides | 2003 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
Topics: Aged; Angiotensin II; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Inflammation; Interleukin-1; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Simvastatin; Tetrazoles; Valine; Valsartan | 2004 |
Vascular effects of diet and statin in hypercholesterolemic patients.
Topics: Biomarkers; C-Reactive Protein; Cell Adhesion Molecules; Coronary Disease; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Male; Middle Aged; Oxidative Stress; Simvastatin; Statistics, Nonparametric | 2004 |
Simvastatin prevents vascular hyporeactivity during inflammation.
Topics: Acetylcholine; Adult; Double-Blind Method; Endotoxemia; Endotoxins; Forearm; Humans; Inflammation; Male; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Nitroglycerin; Norepinephrine; Oxidative Stress; Respiratory Burst; Simvastatin; Tumor Necrosis Factor-alpha; Vasodilation | 2004 |
Simvastatin blunts endotoxin-induced tissue factor in vivo.
Topics: Adult; Biomarkers; Endotoxins; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Monocytes; Platelet Activation; Premedication; Simvastatin; Thrombophilia; Thromboplastin | 2005 |
Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Brain; Brain Ischemia; Creatine Kinase; Double-Blind Method; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Middle Aged; Models, Statistical; Pilot Projects; Simvastatin; Subarachnoid Hemorrhage; Time Factors; Treatment Outcome; Vascular Diseases; Vasospasm, Intracranial | 2005 |
Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antithrombins; beta-Thromboglobulin; Blood Coagulation; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Fenofibrate; Fibrinolytic Agents; Humans; Hypercholesterolemia; Hypolipidemic Agents; Inflammation; Lipid Metabolism; Microscopy, Electron, Scanning; Platelet Activation; Simvastatin; Thrombin; Time Factors; Triglycerides | 2005 |
Short-term simvastatin treatment has no effect on plasma cytokine response in a human in vivo model of low-grade inflammation.
Topics: Adult; Area Under Curve; C-Reactive Protein; Cholesterol, LDL; Cytokines; Endotoxins; Escherichia coli; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immune Tolerance; Inflammation; Interleukin-6; Leukocyte Count; Male; Models, Biological; Receptors, Interleukin-1; Simvastatin; Tumor Necrosis Factor-alpha | 2006 |
Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients.
Topics: Biomarkers; C-Reactive Protein; CD40 Ligand; Female; Fenofibrate; Genetic Predisposition to Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Inflammation; Interleukin-6; Male; Middle Aged; P-Selectin; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Prospective Studies; Simvastatin; Statistics, Nonparametric | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Inflammation; Male; Middle Aged; Phospholipases A; Phospholipases A2; Simvastatin | 2006 |
[Short term simvastatin use in patients with heart failure of ischemic origin. Changes of blood lipids, markers of inflammation and left ventricular function].
Topics: Aged; C-Reactive Protein; Cholesterol; Drug Administration Schedule; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Myocardial Contraction; Myocardial Infarction; Simvastatin; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2006 |
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.
Topics: Adult; Anti-Inflammatory Agents; C-Reactive Protein; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Interleukin-6; Male; Metabolic Syndrome; Middle Aged; Models, Biological; Monocytes; NF-kappa B; Oncogene Protein v-akt; Placebos; Simvastatin; Tumor Necrosis Factor-alpha | 2006 |
Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography.
Topics: Aged; Aorta, Thoracic; Atherosclerosis; Carotid Stenosis; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Inflammation; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Simvastatin | 2006 |
The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.
Topics: Adult; Aged; Antibodies; Atorvastatin; Biomarkers; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Neopterin; Oxidative Stress; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes.
Topics: Adult; Biomarkers; Cholesterol; Cholesterol, LDL; Cytokines; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins, LDL; Male; Monocytes; Simvastatin; Triglycerides | 2007 |
Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Female; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Male; Metabolic Syndrome; Metformin; Middle Aged; Simvastatin | 2007 |
Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis.
Topics: Aged; Anticholesteremic Agents; Aorta; Arthritis, Rheumatoid; Azetidines; Blood Flow Velocity; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Elasticity; Endothelium, Vascular; Ezetimibe; Female; Humans; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Stress, Mechanical | 2007 |
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Circulation; Creatine Kinase; Dose-Response Relationship, Drug; E-Selectin; Enalapril; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Leukocyte Count; Male; Middle Aged; Platelet Count; Pyrroles; Ramipril; Simvastatin; Stroke Volume; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2007 |
Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; CD4 Antigens; CD4-Positive T-Lymphocytes; CD8 Antigens; CD8-Positive T-Lymphocytes; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Rheumatoid Factor; Simvastatin; Th1 Cells; Th2 Cells; Treatment Outcome | 2007 |
In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model.
Topics: Cross-Over Studies; Double-Blind Method; Fluorobenzenes; Gene Expression; Humans; Inflammation; Leukocytes; Male; Placebos; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation.
Topics: Adult; Cell Count; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Endothelial Cells; Flow Cytometry; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipopolysaccharides; Male; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Stem Cells; Sulfonamides; Vascular Endothelial Growth Factor A | 2008 |
Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; CD40 Ligand; Cell Adhesion; Fibrinolysis; Humans; Inflammation; Ligands; Metabolic Syndrome; Models, Biological; P-Selectin; Placebos; Plasminogen Activator Inhibitor 1; Risk; Simvastatin | 2008 |
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome | 2001 |
Effects of simvastatin and atorvastatin on inflammation markers in plasma.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Pyrroles; Simvastatin | 2002 |
161 other study(ies) available for simvastatin and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Proteins; High-Throughput Screening Assays; Humans; Inflammation; Kinetics; Microspheres; Peptide Hydrolases; Peptides; Reproducibility of Results; Temperature | 2010 |
Simvastatin represses inflammation and cell apoptosis in COPD rats via rho/rho kinase signaling pathway.
Topics: Animals; Apoptosis; Inflammation; Pulmonary Disease, Chronic Obstructive; Rats; rho-Associated Kinases; Signal Transduction; Simvastatin | 2023 |
HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation.
Topics: Animals; Autoimmune Diseases; Cardiotonic Agents; Echocardiography; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Metalloproteases; Models, Animal; Myocarditis; Rats; Simvastatin; Ventricular Dysfunction, Left | 2021 |
Simvastatin inhibits the inflammation and oxidative stress of human neutrophils in sepsis via autophagy induction.
Topics: Adult; Aged; Animals; Autophagy; Beclin-1; Cell Survival; Cytokines; Female; Humans; Inflammation; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Neutrophils; Oxidative Stress; Reactive Oxygen Species; Sepsis; Simvastatin; Tumor Necrosis Factor-alpha | 2022 |
Simvastatin Improves Myocardial Ischemia Reperfusion Injury through KLF-Regulated Alleviation of Inflammation.
Topics: Animals; Apoptosis; Inflammation; Kruppel-Like Transcription Factors; Male; Myocardial Reperfusion Injury; Rats; Simvastatin | 2022 |
Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts.
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Down-Regulation; Humans; Inflammation; Lung; Membrane Microdomains; Mice; Mice, Transgenic; SARS-CoV-2; Simvastatin; Virus Replication | 2022 |
Anchoring β-CD on simvastatin-loaded rHDL for selective cholesterol crystals dissolution and enhanced anti-inflammatory effects in macrophage/foam cells.
Topics: Anti-Inflammatory Agents; Atherosclerosis; beta-Cyclodextrins; Cholesterol; Foam Cells; Humans; Inflammation; Lipoproteins, HDL; Macrophages; Plaque, Atherosclerotic; Simvastatin; Solubility | 2022 |
Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia-Induced Bronchopulmonary Dysplasia via the KLF2-Mediated Mechanism.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Antioxidants; Bronchopulmonary Dysplasia; Humans; Hyperoxia; Infant, Newborn; Inflammasomes; Inflammation; Kruppel-Like Transcription Factors; Lung; Lung Injury; NLR Family, Pyrin Domain-Containing 3 Protein; Simvastatin; Transcription Factors | 2022 |
Topical Simvastatin Improves Lesions of Diffuse Normolipemic Plane Xanthoma by Inhibiting Foam Cell Pyroptosis.
Topics: Child; Foam Cells; Humans; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein; Ointments; Pyroptosis; Simvastatin; Xanthomatosis | 2022 |
Simvastatin reduced infiltration of memory subsets of T lymphocytes in the lung tissue during Th2 allergic inflammation.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung; Mice; Mice, Inbred BALB C; Ovalbumin; Simvastatin; Th2 Cells | 2022 |
Simvastatin Reduces NETosis to Attenuate Severe Asthma by Inhibiting PAD4 Expression.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; DNA; Extracellular Traps; Histones; Inflammation; Lipopolysaccharides; Lung; Mice; Neutrophils; Ovalbumin; RNA, Messenger; Simvastatin | 2023 |
Inhibitory Effects of Simvastatin on IL-33-Induced MCP-1 via the Suppression of the JNK Pathway in Human Vascular Endothelial Cells.
Topics: Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Interleukin-33; MAP Kinase Signaling System; Simvastatin | 2023 |
Co-delivery of simvastatin and microRNA-21 through liposome could accelerates the wound healing process.
Topics: Humans; Inflammation; Liposomes; MicroRNAs; Simvastatin; Wound Healing | 2023 |
Simvastatin-Releasing Nanofibrous Peptide Hydrogels for Accelerated Healing of Diabetic Wounds.
Topics: Animals; Diabetes Mellitus, Experimental; Humans; Hydrogels; Inflammation; Mice; Nanofibers; Peptides; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2023 |
Simvastatin Nanoparticles Reduce Inflammation in LPS-Stimulated Alveolar Macrophages.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cell Line; Cell Survival; Inflammation; Inflammation Mediators; Lipopolysaccharides; Macrophages, Alveolar; Nanoparticles; Rats; Signal Transduction; Simvastatin | 2019 |
Internalization of particulate delivery systems by activated microglia influenced the therapeutic efficacy of simvastatin repurposing for neuroinflammation.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Drug Delivery Systems; Drug Repositioning; Inflammation; Interleukin-6; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Microglia; NF-kappa B; Nitric Oxide; Signal Transduction; Simvastatin; Tumor Necrosis Factor-alpha | 2019 |
Comparative benefits of simvastatin and exercise in a mouse model of vascular cognitive impairment and dementia.
Topics: Animals; Cerebrovascular Circulation; Cognitive Dysfunction; Dementia; Disease Models, Animal; Inflammation; Mice; Microglia; Physical Conditioning, Animal; Simvastatin | 2019 |
Nose-to-brain co-delivery of repurposed simvastatin and BDNF synergistically attenuates LPS-induced neuroinflammation.
Topics: Animals; Brain Diseases; Brain-Derived Neurotrophic Factor; Cell Line; Inflammation; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Microglia; Nose; Simvastatin | 2020 |
Simvastatin mediates inhibition of exosome synthesis, localization and secretion via multicomponent interventions.
Topics: Animals; Asthma; Atherosclerosis; Cell Line; Cholesterol; Disease Models, Animal; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Monocytes; Simvastatin | 2019 |
Application of a mechanically responsive, inflammatory macrophage-targeted dual-sensitive hydrogel drug carrier for atherosclerosis.
Topics: Animals; Atherosclerosis; Drug Carriers; Drug Delivery Systems; Hydrogels; Hypolipidemic Agents; Inflammation; Macrophages; Mice; Mice, Knockout; Micelles; Particle Size; Simvastatin; Surface Properties | 2020 |
Beneficial role of simvastatin in experimental autoimmune myositis.
Topics: Animals; Anti-Inflammatory Agents; Autoantibodies; Autoantigens; Female; Humans; Inflammation; Mice; Mice, Inbred BALB C; Muscle Strength; Myosins; Nervous System Autoimmune Disease, Experimental; Simvastatin; Th17 Cells | 2020 |
Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Dopaminergic Neurons; Hippocampus; Inflammation; Mice, Inbred C57BL; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Simvastatin | 2020 |
Sarcodon aspratus polysaccharides ameliorated obesity-induced metabolic disorders and modulated gut microbiota dysbiosis in mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Basidiomycota; Diet, High-Fat; Dietary Supplements; Gastrointestinal Microbiome; Glucose Intolerance; Hypolipidemic Agents; Inflammation; Lipid Metabolism; Liver; Metabolic Diseases; Mice; Obesity; Oxidative Stress; Polysaccharides; Simvastatin; Weight Gain | 2020 |
A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis.
Topics: Atherosclerosis; Humans; Inflammation; Leukocytes; Peptides; Simvastatin | 2020 |
Simvastatin Prevents Long-Term Cognitive Deficits in Sepsis Survivor Rats by Reducing Neuroinflammation and Neurodegeneration.
Topics: Animals; Brain; Cognitive Dysfunction; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Neurodegenerative Diseases; Rats; Rats, Wistar; Sepsis; Simvastatin | 2020 |
Simvastatin Attenuates Abdominal Aortic Aneurysm Formation Favoured by Lack of Nrf2 Transcriptional Activity.
Topics: Angiotensin II; Animals; Aorta; Aortic Aneurysm, Abdominal; Blood Pressure; Collagen; Elastin; Humans; Inflammation; Mice, Inbred C57BL; Mice, Knockout; NF-E2-Related Factor 2; Oxidative Stress; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Signal Transduction; Simvastatin; Transcription, Genetic; Vascular Cell Adhesion Molecule-1 | 2020 |
Protective Effects of Simvastatin on Endotoxin-Induced Acute Kidney Injury through Activation of Tubular Epithelial Cells' Survival and Hindering Cytochrome C-Mediated Apoptosis.
Topics: Acute Kidney Injury; Animals; Apoptosis; bcl-X Protein; Cell Survival; Cytochromes c; Endotoxins; Epithelial Cells; Humans; Inflammation; Kidney; Kidney Tubules; Lipopolysaccharides; Rats; Simvastatin | 2020 |
Ameliorative effects of the traditional Chinese medicine formula
Topics: Animals; Arteriosclerosis Obliterans; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Inflammation; Male; Medicine, Chinese Traditional; NF-kappa B; Rabbits; Simvastatin; Tandem Mass Spectrometry | 2020 |
Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis.
Topics: Animals; Cytokines; Inflammation; Male; Mice; Nitric Oxide; Peritoneal Lavage; Sepsis; Simvastatin; Stem Cells | 2020 |
Simvastatin Enhances Muscle Regeneration Through Autophagic Defect-Mediated Inflammation and mTOR Activation in G93ASOD1 Mice.
Topics: Animals; Autophagy; Denervation; Female; Fibrosis; Inflammation; Mice, Transgenic; Motor Activity; Muscle Development; Muscle, Skeletal; Muscular Atrophy; Mutation; Neuromuscular Junction; Phenotype; Protein Aggregates; Regeneration; Signal Transduction; Simvastatin; Superoxide Dismutase; TOR Serine-Threonine Kinases | 2021 |
Periadventitial Delivery of Simvastatin-Loaded Microparticles Attenuate Venous Neointimal Hyperplasia Associated With Arteriovenous Fistula.
Topics: Animals; Anticholesteremic Agents; Arteriovenous Fistula; Chemokine CCL2; Cyclodextrins; Drug Delivery Systems; Fibrosis; Graft Occlusion, Vascular; Hyperplasia; Inflammation; Kidney Failure, Chronic; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Models, Animal; Neointima; Simvastatin; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A; Vascular Remodeling; Veins | 2020 |
Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves' Ophthalmopathy through the Regulation of FoxO3a Signaling.
Topics: Adult; Chemokine CCL20; Cysteine-Rich Protein 61; Eye; Female; Fibroblasts; Forkhead Box Protein O3; Gene Expression Regulation; Graves Ophthalmopathy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Signal Transduction; Simvastatin | 2021 |
Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation.
Topics: Acute Coronary Syndrome; Aged; C-Reactive Protein; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Clinical Trials as Topic; Datasets as Topic; Ezetimibe, Simvastatin Drug Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Rosuvastatin Calcium; Simvastatin | 2021 |
Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage.
Topics: Animals; Antidepressive Agents, Second-Generation; Apoptosis; Biopterins; Brain; Brain Injuries; Cranial Irradiation; Depression; Fluoxetine; Gamma Rays; Inflammation; Male; Neuroprotective Agents; Nitric Oxide; Oxidative Stress; Rats; Signal Transduction; Sildenafil Citrate; Simvastatin | 2021 |
Anti-inflammatory potential of simvastatin loaded nanoliposomes in 2D and 3D foam cell models.
Topics: Atherosclerosis; Cell Line; Drug Delivery Systems; Foam Cells; Humans; Inflammation; Liposomes; Nanoparticles; Plaque, Atherosclerotic; Simvastatin; Spheroids, Cellular | 2021 |
Anti-Inflammatory Effect of Very High Dose Local Vessel Wall Statin Administration: Poly(L,L-Lactide) Biodegradable Microspheres with Simvastatin for Drug Delivery System (DDS).
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Dioxanes; Drug Delivery Systems; Inflammation; Mice; Mice, Inbred BALB C; Microspheres; Rats; Rats, Wistar; Simvastatin | 2021 |
Hypolipidemic and reduced nitrergic effects of p-hydroxycinnamic diesters extracted from Copernicia prunifera in mice challenged by a high-fat diet.
Topics: Administration, Oral; Animals; Arecaceae; Biomarkers; Body Weight; Coumaric Acids; Diet, High-Fat; Disease Models, Animal; Female; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1beta; Lipid Metabolism; Lipids; Liver; Liver X Receptors; Male; Mice, Inbred C57BL; Plant Extracts; Simvastatin | 2021 |
Anti-inflammatory effects of simvastatin during the resolution phase of experimentally formed venous thrombi.
Topics: Animals; Anti-Inflammatory Agents; Cell Movement; Cytokines; Inflammation; Lipids; Male; Rabbits; Simvastatin; Venous Thrombosis | 2017 |
Downregulations of CD36 and Calpain-1, Inflammation, and Atherosclerosis by Simvastatin in Apolipoprotein E Knockout Mice.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Calpain; CD36 Antigens; Disease Models, Animal; Down-Regulation; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Lipoproteins, LDL; Male; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Simvastatin; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2017 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Biomarkers; Blood Glucose; Cytokines; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Monocytes; RNA, Messenger; Simvastatin | 2017 |
Inhaled simvastatin nanoparticles for inflammatory lung disease.
Topics: Administration, Inhalation; Anti-Inflammatory Agents; Biological Transport; Chemistry, Pharmaceutical; Chronic Disease; Drug Carriers; Drug Liberation; Epithelial Cells; Humans; Inflammation; Lactic Acid; Lung Diseases; Mucus; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Simvastatin; Surface Properties | 2017 |
Nanomechanical testing of drug activities at the cellular level: Case study for endothelium-targeted drugs.
Topics: Actins; Anti-Inflammatory Agents; Cells, Cultured; Dose-Response Relationship, Drug; Drug Delivery Systems; Elasticity; Endothelial Cells; Endothelium, Vascular; Humans; Inflammation; Microscopy, Atomic Force; Microvessels; Prospective Studies; Pyridinium Compounds; Simvastatin; Tumor Necrosis Factor-alpha | 2017 |
Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats.
Topics: Animals; Anticholesteremic Agents; Diabetic Cardiomyopathies; Inflammation; Oxidative Stress; Rats; Simvastatin | 2017 |
Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control.
Topics: Amine Oxidase (Copper-Containing); Animals; Brain; Brain Ischemia; Cell Adhesion; Cell Adhesion Molecules; Cell Line; Disease Models, Animal; E-Selectin; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; NF-kappa B; NF-KappaB Inhibitor alpha; Rats; Rats, Wistar; Simvastatin; Stroke; Vascular Cell Adhesion Molecule-1 | 2018 |
Simvastatin and nanofibrous poly(l-lactic acid) scaffolds to promote the odontogenic potential of dental pulp cells in an inflammatory environment.
Topics: Alkaline Phosphatase; Biomarkers; Cell Differentiation; Cytoprotection; Dental Pulp; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Lipopolysaccharides; Mesenchymal Stem Cells; Nanofibers; Neovascularization, Physiologic; Odontogenesis; Polyesters; RNA, Messenger; Signal Transduction; Simvastatin; Tissue Scaffolds; Young Adult | 2018 |
Profilactic role of simvastatin and mitomycin C in tracheal stenosis after tracheal damage: Study in rats.
Topics: Alkylating Agents; Animals; Anticholesteremic Agents; Female; Fibrosis; Inflammation; Laryngostenosis; Larynx; Mitomycin; Prospective Studies; Rats; Simvastatin; Single-Blind Method; Trachea; Tracheal Stenosis; Tracheotomy | 2018 |
Histologic comparison of direct pulp capping of rat molars with MTA and different concentrations of simvastatin gel.
Topics: Aluminum Compounds; Animals; Calcium Compounds; Dental Pulp Capping; Drug Combinations; Gels; Inflammation; Male; Maxilla; Molar; Oxides; Rats, Wistar; Silicates; Simvastatin | 2018 |
Lipids, inflammation, and chronic kidney disease: a SHARP perspective.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Humans; Inflammation; Lipids; Renal Insufficiency, Chronic; Simvastatin; Treatment Outcome | 2018 |
Simvastatin therapy in adolescent mice attenuates HFD-induced depression-like behavior by reducing hippocampal neuroinflammation.
Topics: Animals; Behavior, Animal; Brain; Depression; Diet, High-Fat; Hippocampus; Hyperlipidemias; Inflammation; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Obesity; Serotonin; Simvastatin | 2019 |
Repurposing simvastatin as a therapy for preterm labor: evidence from preclinical models.
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Disease Models, Animal; Drug Repositioning; Female; Humans; Inflammation; Lipopolysaccharides; Mice; Muscle, Smooth; Myometrium; Obstetric Labor, Premature; Pregnancy; Signal Transduction; Simvastatin; Uterine Contraction | 2019 |
Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6.
Topics: Adult; Anti-Inflammatory Agents; Biomarkers; Case-Control Studies; Female; Humans; Inflammation; Interleukin-10; Interleukin-12; Interleukin-6; Male; Middle Aged; Schizophrenia; Simvastatin; Tumor Necrosis Factor-alpha | 2019 |
Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice.
Topics: Animals; Behavior, Animal; Cytokines; Depression; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Male; Mice; Microglia; NF-kappa B; Simvastatin; Stress, Psychological; Tumor Necrosis Factor-alpha | 2019 |
Crataegus Aronia protects and reverses vascular inflammation in a high fat diet rat model by an antioxidant mechanism and modulating serum levels of oxidized low-density lipoprotein.
Topics: Animals; Antioxidants; Aorta; Crataegus; Diet, High-Fat; Disease Models, Animal; Glutathione; Inflammation; Lipids; Lipoproteins, LDL; Male; Plant Extracts; Rats; Rats, Wistar; Simvastatin; Superoxide Dismutase; Tunica Media; Vascular Diseases | 2019 |
Simvastatin Improves Cardiac Hypertrophy in Diabetic Rats by Attenuation of Oxidative Stress and Inflammation Induced by Calpain-1-Mediated Activation of Nuclear Factor-κB (NF-κB).
Topics: Animals; Calpain; Cardiomegaly; Diabetes Complications; Diabetes Mellitus, Experimental; Disease Models, Animal; Inflammation; Intercellular Adhesion Molecule-1; Male; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide Synthase Type III; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Simvastatin; Streptozocin; Vascular Cell Adhesion Molecule-1 | 2019 |
Simvastatin and Simvastatin-Ezetimibe Improve the Neurological Function and Attenuate the Endothelial Inflammatory Response after Spinal Cord Injury in Rat.
Topics: Animals; Anticholesteremic Agents; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Inflammation; Male; Motor Activity; Neurons; Rats; Rats, Sprague-Dawley; Recovery of Function; Simvastatin; Spinal Cord Injuries | 2019 |
Lipotoxicity-associated inflammation is prevented by guarana (
Topics: Adenosine; Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Caffeine; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperlipidemias; Inflammation; Lymphocytes; Male; Rats; Rats, Wistar; Simvastatin; Theobromine; Theophylline | 2021 |
Simvastatin Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in Nonalcoholic Steatohepatitis Experimental Model.
Topics: Animals; Antioxidants; Choline Deficiency; Endoplasmic Reticulum Stress; Glutathione Peroxidase; Inflammation; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Simvastatin; Superoxide Dismutase | 2019 |
Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies.
Topics: Cell Line; Cell Survival; Drug Administration Schedule; Drug Delivery Systems; Epithelial Cells; Humans; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mucus; Pulmonary Disease, Chronic Obstructive; Simvastatin; Surface Properties; Temperature; Time Factors | 2013 |
Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blotting, Western; Down-Regulation; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Simvastatin | 2013 |
Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
Topics: Animals; Atorvastatin; Biomarkers; Endotoxins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin | 2013 |
Influence and pathophysiological mechanisms of simvastatin on prostatic hyperplasia in spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Endoplasmic Reticulum; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Insulin-Like Growth Factor I; Interleukin-6; Male; Mitochondria; Nitric Oxide Synthase Type III; Prostatic Hyperplasia; Rats; Rats, Inbred SHR; Simvastatin | 2013 |
Monomerization of C-reactive protein requires glycoprotein IIb-IIIa activation: pentraxins and platelet deposition.
Topics: Annexin A5; Blood Platelets; C-Reactive Protein; Cell Adhesion; Healthy Volunteers; Humans; Immunity, Innate; Inflammation; Nerve Tissue Proteins; Phospholipids; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Isoforms; Serum Amyloid P-Component; Shear Strength; Simvastatin; Thrombosis | 2013 |
[Anti-inflammation of simvastatin by polarization of murine macrophages from M1 phenotype to M2 phenotype].
Topics: Animals; Cells, Cultured; Female; Inflammation; Interleukin-10; Interleukin-12; Macrophages; Mice; Mice, Inbred C57BL; Phenotype; Simvastatin | 2013 |
The effect of simvastatin on systemic inflammation and endothelial dysfunction induced by periodontitis.
Topics: Acetylcholine; Alveolar Bone Loss; Animals; Arterial Pressure; C-Reactive Protein; Disease Models, Animal; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Leukocyte Count; Lipids; Male; Nitroprusside; Periodontitis; Random Allocation; Rats; Rats, Wistar; Simvastatin; Vasodilator Agents | 2014 |
Effects of simvastatin, ezetimibe, and their combination on histopathologic alterations caused by adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Arthritis; Azetidines; Cartilage, Articular; Disease Progression; Drug Therapy, Combination; Ezetimibe; Flow Cytometry; Freund's Adjuvant; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Rats; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Mitotic asynchrony induces transforming growth factor-β1 secretion from airway epithelium.
Topics: Aphidicolin; Asthma; Bronchi; Cells, Cultured; Culture Media, Conditioned; Dexamethasone; Epithelial Cells; Epithelium; Fibrosis; Humans; Inflammation; Mitosis; Respiratory Mucosa; Simvastatin; Time Factors; Transforming Growth Factor beta1 | 2014 |
Statin-induced impairment of monocyte migration is gender-related.
Topics: Atherosclerosis; Atorvastatin; Cell Movement; Female; Healthy Volunteers; Heptanoic Acids; Humans; Inflammation; Lipopolysaccharides; Male; Monocytes; Pyrroles; Sex Characteristics; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Simvastatin attenuates the cerebral vascular endothelial inflammatory response in a rat traumatic brain injury.
Topics: Animals; Blotting, Western; Brain Injuries; Cerebrum; Endothelium, Vascular; Immunohistochemistry; Inflammation; Intercellular Adhesion Molecule-1; Male; Rats, Sprague-Dawley; Simvastatin; Staining and Labeling; Time Factors | 2014 |
Simvastatin inhibits inflammation in ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Hindlimb; Inflammation; Male; Mice; Mice, Inbred C57BL; Random Allocation; Reperfusion Injury; Simvastatin | 2014 |
Topical simvastatin improves the pro-angiogenic and pro-osteogenic properties of bioglass putty in the rat calvaria critical-size model.
Topics: Administration, Topical; Angiogenesis Inducing Agents; Animals; Bone Diseases; Bone Matrix; Bone Substitutes; Capillaries; Ceramics; Collagen; Disease Models, Animal; Inflammation; Male; Osteocytes; Osteogenesis; Rats; Rats, Wistar; Simvastatin; Skull | 2014 |
Simvastatin combined with antioxidant attenuates the cerebral vascular endothelial inflammatory response in a rat traumatic brain injury.
Topics: Animals; Antioxidants; Brain Injuries; Cerebral Veins; Drug Combinations; Endothelial Cells; Humans; Inflammation; Nitric Oxide Synthase; Rats; Simvastatin | 2014 |
Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; Lung; Mice, Inbred BALB C; Simvastatin | 2014 |
Simvastatin reduces fibrosis and protects against muscle weakness after massive rotator cuff tear.
Topics: Acetyl-CoA C-Acetyltransferase; Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; CCAAT-Binding Factor; Chronic Disease; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Inflammation; Male; Muscle Contraction; Muscle Fibers, Skeletal; Muscle Weakness; Myosin Heavy Chains; PPAR gamma; Rats; Rats, Sprague-Dawley; Regeneration; Rotator Cuff; Rotator Cuff Injuries; Rupture; Shoulder Pain; Simvastatin | 2015 |
Simvastatin attenuates angiotensin II‑induced inflammation and oxidative stress in human mesangial cells.
Topics: Angiotensin II; Anticholesteremic Agents; Cell Line; Chemokine CCL2; Cyclooxygenase 2; Dinoprostone; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Mesangial Cells; NADPH Oxidases; Oxidative Stress; PPAR gamma; Protein Kinase C; Reactive Oxygen Species; RNA, Messenger; Simvastatin; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2015 |
Simvastatin attenuates sepsis-induced blood-brain barrier integrity loss.
Topics: Animals; Blood Pressure; Blood-Brain Barrier; Brain; Brain Diseases; Chemokine CXCL2; Claudin-3; Claudin-5; Drug Evaluation, Preclinical; Edema; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Malondialdehyde; Oxidative Stress; Random Allocation; Rats, Sprague-Dawley; Sepsis; Simvastatin; Survival Rate | 2015 |
Simvastatin mitigates functional and structural impairment of lung and right ventricle in a rat model of cigarette smoke-induced COPD.
Topics: Animals; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heart Ventricles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung; Male; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Respiratory Function Tests; RNA-Binding Proteins; Simvastatin; Smoking | 2014 |
Simvastatin does not reduce chemokine production in obesity without comorbidities.
Topics: Adipose Tissue; Adult; Biomarkers; C-Reactive Protein; Chemokine CCL2; Chemokine CCL5; Chemokine CXCL10; Chemokine CXCL9; Chemokines; Cholesterol; Comorbidity; Female; Humans; Hypolipidemic Agents; Inflammation; Interleukin-8; Middle Aged; Obesity; Simvastatin; Triglycerides; Young Adult | 2015 |
The Effect of Simvastatin on Infection-Induced Inflammatory Response of Human Fetal Membranes.
Topics: Cytokines; Embryo Culture Techniques; Extraembryonic Membranes; Female; Fetus; Humans; Inflammation; Lipopolysaccharides; Pregnancy; Receptors, Cytokine; Simvastatin; Tissue Inhibitor of Metalloproteinase-2 | 2015 |
Stroke mimicking relapse in a patient with CLIPPERS syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Brain Stem; Encephalomyelitis; Gadolinium; Humans; Hypoglycemic Agents; Inflammation; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Recurrence; Simvastatin; Stroke | 2015 |
Anti-inflammatory Therapy With Simvastatin Improves Neuroinflammation and CNS Function in a Mouse Model of Metachromatic Leukodystrophy.
Topics: Animals; Anti-Inflammatory Agents; Central Nervous System; Chemokine CCL2; Chemokine CCL4; Demyelinating Diseases; Disease Models, Animal; Humans; Inflammation; Leukodystrophy, Metachromatic; Mice; Simvastatin; Spinal Cord; Tumor Necrosis Factor-alpha | 2015 |
Icariin Attenuates High-cholesterol Diet Induced Atherosclerosis in Rats by Inhibition of Inflammatory Response and p38 MAPK Signaling Pathway.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Dyslipidemias; Flavonoids; Inflammation; Interleukin-6; Lipids; Male; Malondialdehyde; MAP Kinase Signaling System; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; RNA, Messenger; Simvastatin; Superoxide Dismutase; Triglycerides; Tumor Necrosis Factor-alpha | 2016 |
Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration.
Topics: Animals; Cell Differentiation; Cell Proliferation; Central Nervous System; Chemokine CCL5; Encephalomyelitis, Autoimmune, Experimental; Female; Inflammation; Interleukin-12 Subunit p40; Interleukin-6; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Simvastatin; Th1 Cells; Th17 Cells; Transforming Growth Factor beta | 2015 |
Role of Integrin β4 in Lung Endothelial Cell Inflammatory Responses to Mechanical Stress.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Disease Models, Animal; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Integrin beta4; Mice; Mice, Inbred C57BL; Mutagenesis, Site-Directed; Permeability; Phosphorylation; Protein Structure, Tertiary; Pulmonary Artery; Simvastatin; Stress, Mechanical; Ventilator-Induced Lung Injury | 2015 |
Analysis of Bone Repair and Inflammatory Process Caused by Simvastatin Combined With PLGA+HA+βTCP Scaffold.
Topics: Animals; Bone Regeneration; Calcium Phosphates; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lactic Acid; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Simvastatin; Skull; Tissue Scaffolds | 2016 |
[Effects of simvastatin on airway inflammation and airway mucus hypersecretion in rats with chronic obstructive pulmonary disease].
Topics: Animals; Bronchi; Bronchoalveolar Lavage Fluid; Enzyme-Linked Immunosorbent Assay; Inflammation; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Lung; Male; Mucin 5AC; Mucus; NF-kappa B; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Simvastatin; Smoke | 2015 |
Simvastatin and zinc synergistically enhance osteoblasts activity and decrease the acute response of inflammatory cells.
Topics: Acute-Phase Reaction; Animals; Bone Regeneration; Cell Differentiation; Cells, Cultured; Down-Regulation; Drug Synergism; Humans; Inflammation; Mice; Monocytes; Osteoblasts; Osteogenesis; Reactive Oxygen Species; Simvastatin; Zinc | 2016 |
[Effect of aminophylline and simvastatin on airway inflammation and mucus hypersecretion in rats with chronic obstructive pulmonary disease].
Topics: Aminophylline; Animals; Bronchi; Bronchoalveolar Lavage Fluid; Cytokines; Inflammation; Lipopolysaccharides; Lung; Male; Mucin 5AC; Mucus; Pulmonary Disease, Chronic Obstructive; Random Allocation; Rats; Rats, Sprague-Dawley; Simvastatin; Smoke; Smoking; Toll-Like Receptor 4 | 2016 |
Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cell Proliferation; Cytokines; Endoplasmic Reticulum Stress; High-Throughput Screening Assays; Humans; Hydrocarbons, Fluorinated; Inflammation; Inflammation Mediators; Lipid Metabolism; Lipopolysaccharides; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; Oxidative Stress; Plaque, Atherosclerotic; Prednisolone; RAW 264.7 Cells; Reactive Oxygen Species; Signal Transduction; Simvastatin; Stilbenes; Sulfonamides; Transfection | 2016 |
Pleiotropic Effects of Simvastatin on Wound Healing in Diabetic Mice.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Physiologic; Simvastatin; Wound Healing | 2016 |
Simvastatin Therapy in the Acute Stage of Traumatic Brain Injury Attenuates Brain Trauma-Induced Depression-Like Behavior in Rats by Reducing Neuroinflammation in the Hippocampus.
Topics: Acute Disease; Animals; Behavior, Animal; Brain Injuries, Traumatic; Depression; Disease Models, Animal; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Injections, Intraperitoneal; Male; Rats; Rats, Sprague-Dawley; Simvastatin | 2017 |
Simvastatin Treatment Modulates Mechanically-Induced Injury and Inflammation in Respiratory Epithelial Cells.
Topics: Cell Line; Epithelial Cells; Humans; Inflammation; Pulmonary Alveoli; Respiratory Mucosa; Simvastatin | 2016 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Female; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Uric Acid | 2016 |
Simvastatin alleviates airway inflammation and remodelling through up-regulation of autophagy in mouse models of asthma.
Topics: Adenine; Airway Remodeling; Animals; Asthma; Autophagosomes; Autophagy; Autophagy-Related Protein 5; Beclin-1; Cytokines; Disease Models, Animal; Extracellular Matrix; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferon-gamma; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Myocytes, Smooth Muscle; Ovalbumin; Simvastatin; Up-Regulation | 2017 |
Simvastatin Alleviates Pathology in a Rat Model of Preeclampsia Involving ERK/MAPK Pathway.
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Malondialdehyde; MAP Kinase Signaling System; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Oxidative Stress; Pre-Eclampsia; Pregnancy; Rats; Simvastatin; Tumor Necrosis Factor-alpha; Up-Regulation; Vascular Endothelial Growth Factor A | 2017 |
Simvastatin inhibits homocysteine-induced CRP generation via interfering with the ROS-p38/ERK1/2 signal pathway in rat vascular smooth muscle cells.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; C-Reactive Protein; Cells, Cultured; Dose-Response Relationship, Drug; Homocysteine; Inflammation; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Risk Factors; Signal Transduction; Simvastatin | 2017 |
Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Cell Adhesion; Cytokines; Drug Therapy, Combination; Ezetimibe; Inflammation; Knee Joint; Leukocyte Rolling; Leukocytes; Rats; Simvastatin | 2017 |
mZD7349 peptide-conjugated PLGA nanoparticles directed against VCAM-1 for targeted delivery of simvastatin to restore dysfunctional HUVECs.
Topics: Anti-Inflammatory Agents; Cells, Cultured; Drug Carriers; Drug Compounding; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lactic Acid; Nanoparticles; Nitric Oxide Synthase Type III; Peptides, Cyclic; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Serine; Simvastatin; Solubility; Time Factors; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2017 |
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Coronary Artery Disease; Disease Models, Animal; Endothelium, Vascular; Inflammation; Lipids; Male; Rabbits; Risk; Simvastatin; Stress, Mechanical; Tetrazoles; Valine; Valsartan | 2009 |
Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation.
Topics: Cell Hypoxia; Cell Line; Endothelial Cells; Endothelium, Vascular; Humans; Hypolipidemic Agents; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammation; Models, Biological; Neovascularization, Pathologic; Oxidative Stress; Simvastatin; Tumor Necrosis Factor-alpha | 2008 |
Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells.
Topics: Animals; Blotting, Western; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Endothelial Cells; Enzyme Activation; Humans; Hypolipidemic Agents; Immunoenzyme Techniques; Inflammation; Lipoproteins, HDL; Lysophospholipids; Mice; Monocytes; Nitric Oxide Synthase; PPAR alpha; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; Scavenger Receptors, Class B; Simvastatin; Sphingosine; Transfection; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 2008 |
Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Carrageenan; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Indomethacin; Inflammation; Male; Neutrophil Infiltration; Rats; Rats, Wistar; Simvastatin | 2009 |
Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways.
Topics: Animals; Cholesterol; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Inflammation; Isoflavones; Janus Kinase 2; Leptin; Lipid Metabolism; Liver; Male; Phytotherapy; Plant Extracts; Pueraria; Rats; Rats, Wistar; Receptors, Leptin; RNA, Messenger; Signal Transduction; Simvastatin; STAT3 Transcription Factor; Triglycerides | 2009 |
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Line; Cell Movement; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Male; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.
Topics: Angiotensin II; Gene Expression Regulation; Glucose; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation; Kidney; Mesangial Cells; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Tetrazoles; Valine; Valsartan | 2009 |
Re: Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study.
Topics: Animals; Bone Morphogenetic Protein 2; Bone Regeneration; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pravastatin; Rabbits; Simvastatin | 2009 |
Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Time Factors; Up-Regulation | 2009 |
Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond.
Topics: Animals; Asthma; Biosynthetic Pathways; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mevalonic Acid; Mice; Mice, Inbred BALB C; Simvastatin | 2009 |
Ezetimibe - new anti-atherogenic properties?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Movement; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; C-Reactive Protein; Diuretics; Female; Glomerular Filtration Rate; Humans; Hypolipidemic Agents; Inflammation; Kaplan-Meier Estimate; Kidney Function Tests; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors; Simvastatin; Treatment Outcome | 2009 |
Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus.
Topics: Actins; Animals; Cell Line; Cytoskeleton; Humans; Inflammation; Inflammation Mediators; Macrophages; Membrane Microdomains; Mice; Microbial Viability; Opsonin Proteins; Phagocytosis; Protein Prenylation; ras Proteins; Receptors, IgG; Respiratory Burst; rho GTP-Binding Proteins; Signal Transduction; Simvastatin; Staphylococcus aureus | 2010 |
Effect of simvastatin on proinflammatory cytokines production during lipopolysaccharide-induced inflammation in rats.
Topics: Administration, Oral; Animals; Cytokines; Dose-Response Relationship, Drug; Inflammation; Lethal Dose 50; Lipopolysaccharides; Male; Rats; Rats, Wistar; Simvastatin; Time Factors | 2009 |
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study.
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Insulin; Lipoproteins, LDL; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Thiazolidinediones | 2009 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids; Inflammation; Male; Metabolic Syndrome; Microcirculation; Muscle, Skeletal; Nitric Oxide; Probucol; Pyrroles; Rats; Rats, Zucker; Simvastatin; Time Factors | 2009 |
Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cell Survival; Disease Models, Animal; Endothelial Cells; Fibrosis; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension, Renovascular; Inflammation; Kidney; Lipoproteins, LDL; Macrophages; Oxidative Stress; Renal Circulation; Simvastatin; Stem Cells; Sus scrofa | 2010 |
Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients: effect of statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Neutrophils; Oxidative Stress; Simvastatin | 2010 |
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex | 2010 |
Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis.
Topics: Apoptosis; Biomarkers; C-Reactive Protein; Case-Control Studies; Endothelial Cells; Humans; Hypolipidemic Agents; Inflammation; Kidney Failure, Chronic; Lipids; Monocytes; Oxidative Stress; Renal Dialysis; Simvastatin | 2010 |
Anti-inflammatory and monocyte-suppressing effects of simvastatin in patients with impaired fasting glucose.
Topics: Adult; Aged; Anti-Inflammatory Agents; C-Reactive Protein; Chemokine CCL2; Fasting; Female; Glucose; Humans; Hypercholesterolemia; Inflammation; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Monocytes; Simvastatin; Tumor Necrosis Factor-alpha | 2011 |
Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?
Topics: Aerosols; Animals; Arginase; Arginine; Asthma; Blotting, Western; Coloring Agents; Disease Models, Animal; Goblet Cells; Hydroxyproline; Hyperplasia; Immunohistochemistry; Inflammation; Lung; Mice; Nitrates; Nitrites; Ovalbumin; Simvastatin; Transforming Growth Factor beta1 | 2010 |
Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileitis; Inflammation; Intestine, Small; Mice; Mice, Inbred C57BL; Resveratrol; Simvastatin; Stilbenes; Th1 Cells; Toxoplasma | 2010 |
Different effects of simvastatin on ex vivo monocyte cytokine release in patients with hypercholesterolemia and impaired glucose tolerance.
Topics: Blood Glucose; C-Reactive Protein; Cholesterol; Cytokines; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Inflammation; Male; Middle Aged; Monocytes; Simvastatin; Triglycerides | 2010 |
PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Intestinal Mucosa; Intestines; Kidney; Liver; Lung; Mice; Mice, Knockout; Multiple Organ Failure; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; PPAR alpha; Shock; Simvastatin; Tumor Necrosis Factor-alpha; Up-Regulation; Zymosan | 2011 |
Endotoxin-induced cardiovascular dysfunction in mice: effect of simvastatin.
Topics: Acetylcholine; Acute Lung Injury; Animals; Aorta; Bronchoalveolar Lavage Fluid; Cardiovascular Diseases; Cell Differentiation; Endothelium, Vascular; Heart; Inflammation; Interleukin-6; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred C57BL; Nitroprusside; Permeability; Simvastatin; Vasodilation; Vasodilator Agents; Veins | 2011 |
Simvastatin inhibits pro-inflammatory mediators through induction of heme oxygenase-1 expression in lipopolysaccharide-stimulated RAW264.7 macrophages.
Topics: Animals; Blotting, Western; Free Radicals; Heme Oxygenase-1; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-10; Lipopolysaccharides; Macrophages; Mice; NF-kappa B; Nitric Oxide Synthase Type II; Nitrites; Simvastatin; Tumor Necrosis Factor-alpha | 2011 |
Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis, inflammatory reaction, and tissue damage in a rabbit model of toxin-heat and blood stasis syndrome.
Topics: Analysis of Variance; Animals; Atherosclerosis; Blood Circulation; Disease Models, Animal; Drugs, Chinese Herbal; Endothelium, Vascular; Immunohistochemistry; Inflammation; Male; Rabbits; Random Allocation; Sensitivity and Specificity; Simvastatin; Systemic Inflammatory Response Syndrome; Thrombosis | 2013 |
Critical role for integrin-β4 in the attenuation of murine acute lung injury by simvastatin.
Topics: Acute Lung Injury; Animals; Chemokine CCL2; Endothelial Cells; Gene Expression Regulation; Humans; Inflammation; Integrin beta4; Interleukin-6; Interleukin-8; Lipopolysaccharides; Mice; Phosphorylation; Phosphotyrosine; Simvastatin | 2012 |
Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit model.
Topics: Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Atherosclerosis; Blood Coagulation; Cholesterol, Dietary; Cholesterol, LDL; Cytokines; Drugs, Chinese Herbal; Inflammation; Inflammation Mediators; Lipids; Macrophages; Magnoliopsida; Male; Myocytes, Smooth Muscle; Phytotherapy; Plaque, Atherosclerotic; Rabbits; Simvastatin; Triglycerides | 2012 |
Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinic-polycytidylic acid-induced pneumonia.
Topics: Animals; Anti-Inflammatory Agents; Bronchi; Cell Line, Tumor; Chemokine CCL5; Disease Models, Animal; Doxycycline; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung; Mice; Mice, Inbred BALB C; Neutrophils; Pneumonia; Poly I-C; RNA, Small Interfering; Simvastatin; STAT3 Transcription Factor | 2013 |
Can statins reduce the inflammatory response associated with preterm birth in an animal model?
Topics: Animals; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Pravastatin; Pregnancy; Premature Birth; Simvastatin | 2012 |
Simvastatin protects against T cell immune dysfunction in abdominal sepsis.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Cytokines; HMGB1 Protein; Inflammation; Male; Mice; Sepsis; Simvastatin; Spleen; T-Lymphocytes, Regulatory | 2012 |
Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy.
Topics: Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Cholesterol; Epithelium; Inflammation; Leukocytes; Macrophages; Male; Monomeric GTP-Binding Proteins; Neutrophils; Nicotiana; Oxidative Stress; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Inbred SHR; Respiratory Function Tests; rho GTP-Binding Proteins; Simvastatin; Smoke; Treatment Outcome | 2013 |
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin; Treatment Outcome; Vitamin D | 2013 |
Statins as potent antiinflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Toxins; Cardiotonic Agents; Cell Movement; Endothelium, Vascular; Hemolysin Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Leukocytes; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Simvastatin; Toxemia | 2002 |
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cell Line; Cell Survival; Down-Regulation; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Proteins; Inflammation; Lovastatin; Muscle, Smooth, Vascular; NF-kappa B; NF-KappaB Inhibitor alpha; Plasminogen Activator Inhibitor 1; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrroles; RNA, Messenger; Simvastatin; Transcription Factor AP-1; Transcription Factors; Vascular Endothelial Growth Factor A | 2003 |
Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats.
Topics: Animals; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipopolysaccharides; Male; Nitrates; Nitric Oxide; Pressure; Protein Isoforms; Rats; Rats, Wistar; Shock, Septic; Simvastatin; Time Factors | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors.
Topics: Adjuvants, Immunologic; Animals; CCAAT-Enhancer-Binding Proteins; Drug Synergism; Female; Gene Expression Regulation; Inflammation; Interleukin-12; Interleukin-12 Subunit p40; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C57BL; Promoter Regions, Genetic; Protein Subunits; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Simvastatin; Transcription Factor AP-1; Transcription Factors | 2004 |
Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients.
Topics: Arteriosclerosis; C-Reactive Protein; CD40 Ligand; E-Selectin; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Inflammation; Kidney Failure, Chronic; Male; Middle Aged; P-Selectin; Peritoneal Dialysis, Continuous Ambulatory; Platelet Aggregation; Simvastatin; Solubility; von Willebrand Factor | 2004 |
Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs.
Topics: Animals; Antioxidants; Ascorbic Acid; Atrial Fibrillation; Calcium Channels, L-Type; Cardiac Pacing, Artificial; Dogs; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; Refractory Period, Electrophysiological; Simvastatin; Vitamin E | 2004 |
Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury.
Topics: Animals; Biomarkers; Bronchoalveolar Lavage Fluid; Capillary Permeability; Endothelial Cells; Endotoxins; Gene Expression Profiling; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipopolysaccharides; Lung; Lung Diseases; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Simvastatin | 2005 |
Simvastatin: pharmacological response in experimental hyperfibrinogenaemias.
Topics: Animals; Aorta, Thoracic; Endothelium, Vascular; Fibrinogen; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Rats; Simvastatin; Tunica Intima | 2005 |
Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs.
Topics: Administration, Oral; Analysis of Variance; Animals; Biopsy; Chronic Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inflammation; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Nitric Oxide Synthase; Pulmonary Artery; Pulmonary Emphysema; Rats; Rats, Sprague-Dawley; Risk Factors; Simvastatin; Smoking; Time Factors | 2005 |
Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist.
Topics: Anticholesteremic Agents; C-Reactive Protein; Down-Regulation; Gene Expression Regulation; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1; Interleukin-6; Nitric Oxide; Pravastatin; RNA, Messenger; Simvastatin; STAT3 Transcription Factor; Tumor Cells, Cultured | 2006 |
Effect of statin therapy on serum trace element status in dyslipidaemic subjects.
Topics: Adult; Antioxidants; Atorvastatin; Blood Chemical Analysis; Ceruloplasmin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Trace Elements | 2005 |
Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes.
Topics: Amino Acid Chloromethyl Ketones; Antibodies; Atorvastatin; Caspase 1; CD28 Antigens; CD3 Complex; Cells, Cultured; Enzyme Activation; Heptanoic Acids; Humans; Inflammation; Interferon-gamma; Interleukin-1; Interleukin-12; Interleukin-18; Mevalonic Acid; Mitosis; Monocytes; Pyrroles; Simvastatin; Solubility; T-Lymphocytes | 2006 |
Effects of preoperative statin therapy on cytokines after cardiac surgery.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Heart Arrest, Induced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Interleukin-6; Male; Postoperative Complications; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
A role for geranylgeranylation in interleukin-1beta secretion.
Topics: Anti-Inflammatory Agents; Bodily Secretions; Diphosphonates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Leukocytes, Mononuclear; Mevalonic Acid; Pamidronate; Phosphotransferases (Alcohol Group Acceptor); Protein Prenylation; Simvastatin; Terpenes | 2006 |
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats.
Topics: Actins; Animals; Blood Pressure; Blotting, Western; Collagen; Disease Progression; Fibrinogen; Fibrinolysin; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microscopy, Electron; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Podocytes; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides | 2007 |
The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery.
Topics: Aged; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Coronary Disease; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Predictive Value of Tests; Regression Analysis; Risk Factors; Saphenous Vein; Simvastatin; Vascular Patency | 2007 |
Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect.
Topics: Animals; Anticholesteremic Agents; Biocompatible Materials; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Regeneration; Bone Substitutes; Calcium Sulfate; Drug Combinations; Gene Expression Regulation; Inflammation; Male; Rats; Rats, Wistar; Simvastatin; Skull; Time Factors; Transforming Growth Factor beta | 2007 |
2,3,4',5-Tetrahydroxystilbene-2-O-beta-D-glucoside suppresses matrix metalloproteinase expression and inflammation in atherosclerotic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Glucosides; Inflammation; Male; Matrix Metalloproteinases; Rats; Rats, Sprague-Dawley; Simvastatin; Stilbenes | 2008 |
Simvastatin suppresses lung inflammatory response in a rat cardiopulmonary bypass model.
Topics: Animals; Cardiopulmonary Bypass; Chemokine CCL2; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Innate; Inflammation; Interleukin-6; Lung; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Simvastatin; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2007 |
Invited commentary. New evidence regarding statins as antiinflammatory agents in the context of ECC.
Topics: Animals; Anti-Inflammatory Agents; Cardiopulmonary Bypass; Extracorporeal Circulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Models, Animal; Rats; Simvastatin | 2007 |
Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide.
Topics: Animals; Anticholesteremic Agents; Arachidonic Acids; Dopamine; Drug Interactions; Gene Expression Regulation; Inflammation; Male; Nerve Degeneration; Nerve Tissue Proteins; Nitric Oxide Synthase Type II; Rats; Rats, Wistar; Simvastatin; Substantia Nigra; Tumor Necrosis Factor-alpha | 2008 |
Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products.
Topics: C-Reactive Protein; Cell Adhesion; Cells, Cultured; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mevalonic Acid; Monocytes; NF-kappa B; Polyisoprenyl Phosphates; Receptors, IgG; RNA, Small Interfering; Sesquiterpenes; Simvastatin; Umbilical Veins; Up-Regulation; Vascular Cell Adhesion Molecule-1 | 2008 |
Inflammation and lipid accumulation in xanthoma disseminatum: Therapeutic considerations.
Topics: Adult; Histiocytosis, Non-Langerhans-Cell; Humans; Inflammation; Lipid Metabolism; Male; Pyrazines; Rosiglitazone; Simvastatin; Thiazolidinediones | 2008 |
Simvastatin protects against amyloid beta and HIV-1 Tat-induced promoter activities of inflammatory genes in brain endothelial cells.
Topics: Amyloid beta-Peptides; Anticholesteremic Agents; Astrocytes; Brain; Cell Line, Transformed; Cytoprotection; Endothelial Cells; Gene Expression Regulation; HIV-1; Humans; Inflammation; Inflammation Mediators; Jurkat Cells; Peptide Fragments; Promoter Regions, Genetic; Selectins; Simvastatin; tat Gene Products, Human Immunodeficiency Virus; Transcriptional Activation | 2008 |
After ENHANCE: is more LDL cholesterol lowering even better?
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Carotid Artery Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation; Lipid Metabolism; Simvastatin | 2008 |
Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; C-Reactive Protein; Humans; Hypercholesterolemia; Inflammation; Interleukin-6; Interleukin-8; Male; Middle Aged; Simvastatin; Tumor Necrosis Factor-alpha | 2001 |